en Clinical Neuroscience Clinical Neuroscience Review Review <div style="text-align: justify;"><strong>Introduction</strong>: Patients with myasthenia gravis (MG), an autoimmune disease affecting the neuromuscular junction, exhibits varying rates of COVID-19 infection across different studies. This systematic review and meta-analysis aim to estimate the pooled prevalence of COVID-19 infection in individuals with MG.&nbsp;<br> <strong>Methods</strong>: We systematically searched PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and gray literature, including references to the research published before October 2021. The total number of participants, the first author, the publication year, the country of origin, the number of MG patients, their symptoms, hospitalization rates, and deaths were all extracted as study data.&nbsp;<br> <strong>Results</strong>: Our literature search yielded 253 articles, of which 75 remained after removing duplicates. Finally, 18 articles were included in the meta-analysis. The pooled prevalence of COVID-19 infection in MG cases was found to be 2% (95% CI, 1%, 3%; I2=85%, P<0.001). Additionally, the pooled prevalence of hospitalization among those with COVID-19 infection was 43% (95% CI, 26%, 60%; I2=97.6%; P<0.001), and the pooled prevalence of MG exacerbation was 33% (95% CI, 20%, 46%; I2=92.6%; P<0.001).&nbsp;<br> <strong>Conclusion</strong>: In summary, this systematic review and meta-analysis reveal that the pooled prevalence of COVID-19 infection in individuals with MG is 2%.</div> Myasthenia gravis (MG), COVID-19, Prevalence 175 184 http://bcn.iums.ac.ir/browse.php?a_code=A-10-4360-5&slc_lang=en&sid=1 Amirhossein Nafari amir.nafari@yahoo.com 13700319475328460048918 0009-0008-7483-125X No Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Seyedpouzhia Shojaei p.shojaei@yahoo.com 13700319475328460048919 13700319475328460048919 No Critical Care Quality Improvement Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Reza Jalili Khoshnood reza.jalili@yahoo.com 13700319475328460048920 13700319475328460048920 No Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Mahsa Ghajarzadeh m.ghajarzadeh@gmail.com 13700319475328460048921 13700319475328460048921 No Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Arash Tafreshinejad arash.tafreshi@yahoo.com 13700319475328460048922 13700319475328460048922 No Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Saeid Safari drsafari.s@gmail.com 13700319475328460048923 13700319475328460048923 Yes Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Omid Mirmosayyeb omid.mirmosayyeb@yahoo.com 13700319475328460048924 13700319475328460048924 No Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.